Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact

Cardiac Amyloid Quantification Using 124I-Evuzamitide PET/CTCompared With 18F-Florbetapir PET/CT

Sep 30, 2023 Posters & Publications

AUTHORS: Clerc OF1, Cuddy SAM1, Robertson M2, Benz DC1, Vijayakumar S1, Canseco Neri J1, Chemburkar V1, Kijewski MF2, Di Carli MF2, Bianchi G1, Falk RH1, Dorbala S1,2 1 Cardiac Amyloidosis Program, Department of Internal Medicine, Brigham and Women’s Hospital, Boston,...

Iodine-124-Evuzamitide PET/CT in Systemic Amyloidosis: Safety Evaluation & Reproducibility of Cardiac Uptake Quantitation

Sep 30, 2023 Posters & Publications

AUTHORS: Gregory Bell,1 Claire Sherman,1 Akari Yamagami,1 I-Ling Hsuie,1 Dustin C. Powell,2 Ming Yang,3 Matthew D. L. Kay,4 Deepak Behera,5 Matthew F. Covington,6 Don C. Yoo,7 Phillip H. Kuo8 1Attralus, Inc., San Francisco, CA, USA; 2Hendersonville Radiological...

First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Ahmad Masri, Derrick Gillan, Jessica Cardin, Jad Chehab, Adam Brown, Eva Medvedova, Nadine Mallak Amyloidosis Center, Knight Cardiovascular and Cancer Institutes, and Molecular Imaging and Therapy Section, Oregon Health & Science University, Portland, OR...

Relationship Between Myocardial 124I-evuzamitide Uptake and Cardiac Structure and Function: A Cardiac PET/MRI Study

Sep 30, 2023 Posters & Publications

AUTHORS: Ahmad Masri, Jessica Cardin, Derrick Gillan, Adam Brown, Jad Chehab, Eva Medvedova, Nadine Mallak Amyloidosis Center, Knight Cardiovascular and Cancer Institutes, and Molecular Imaging and Therapy Section, Oregon Health & Science University, Portland, OR...

Quantitative assessment of changes in cardiac and extracardiac amyloid load in patients with AL and ATTR amyloidosis, measured by PET/CT imaging using the pan-amyloid reactive radiotracer iodine (124I) evuzamitide

Sep 30, 2023 Posters & Publications

AUTHORS: Alan Stuckey1, Stephen Kennel1, Emily Martin1, R. Eric Heidel1, Spencer Guthrie2, Jonathan Wall1 1University of Tennessee Graduate School of Medicine, USA 2Attralus Inc, San Francisco, California, USA Click Here to View...
« Older Entries

Recent Posts

  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
  • Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.